Breaking News Instant updates and real-time market news.

FEYE

FireEye

$16.96

0.22 (1.31%)

, ASUR

Asure Software

$11.64

0.2 (1.75%)

04:55
10/04/18
10/04
04:55
10/04/18
04:55

FireEye to hold a summit

FireEye Cyber Defense Summit 2018 will be held in Washington, D.C. on October 1-4.

FEYE

FireEye

$16.96

0.22 (1.31%)

ASUR

Asure Software

$11.64

0.2 (1.75%)

ATNI

ATN International

$70.81

-1.04 (-1.45%)

ROG

Rogers Corporation

$142.02

0.06 (0.04%)

CERS

Cerus

$7.02

-0.08 (-1.13%)

JE

Just Energy

$3.26

-0.12 (-3.55%)

MELI

MercadoLibre

$354.24

0.29 (0.08%)

REX

REX American Resources

$78.47

2.59 (3.41%)

KEYS

Keysight Technologies

$66.11

0.305 (0.46%)

BERY

Berry Global

$47.57

-0.72 (-1.49%)

ITW

Illinois Tool Works

$143.70

-1.04 (-0.72%)

OPHT

Ophthotech

$2.53

0.08 (3.27%)

COT

Cott Corp.

$15.10

-0.345 (-2.23%)

PMTS

CPI Card Group

$3.00

(0.00%)

LMNX

Luminex

$28.72

-0.17 (-0.59%)

YGYI

Youngevity

$6.78

-0.6 (-8.13%)

OTCM

OTC Markets

$0.00

(0.00%)

  • 10

    Oct

  • 10

    Oct

  • 12

    Oct

  • 22

    Oct

  • 06

    Nov

  • 10

    Dec

FEYE FireEye
$16.96

0.22 (1.31%)

08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
07/09/18
07/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. FireEye (FEYE) upgraded to Overweight from Neutral at Piper Jaffray with analyst Andrew Nowinski saying a recent round of channel checks showed a "significant improvement" in demand trends for the company. 2. BP (BP) upgraded to Top Pick from Outperform at RBC Capital with analyst Biraj Borkhataria saying the company's visibility for volume growth will lead to higher cash flows from operations. 3. Capital One (COF) upgraded to Outperform from Perform at Oppenheimer with analyst Ben Chittenden saying the delinquency formation is improving and Q2 expectations seem too low to him. 4. Dunkin' Brands (DNKN) upgraded to Neutral from Underperform at Longbow with analyst Alton Stump saying his conversations with U.S. franchisees lead him to believe the company's Q2 same-store sales rose 0.5-1.0%, which would be in-line with the consensus view and slightly better than his prior forecast for them to have been flat with last year. 5. Baidu (BIDU) upgraded to Outperform from Neutral at Credit Suisse and to Overweight from Sector Weight at KeyBanc. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/09/18
PIPR
07/09/18
UPGRADE
Target $20
PIPR
Overweight
FireEye upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Andrew Nowinski upgraded FireEye to Overweight and raised his price target for the shares to $20 from $17. The analyst sees improving demand trends for FireEye following his firm's Q2 security reseller survey.
07/09/18
PIPR
07/09/18
UPGRADE
Target $20
PIPR
Overweight
Piper Jaffray upgrades FireEye to Overweight on improving demand trends
Piper Jaffray analyst Andrew Nowinski upgraded FireEye (FEYE) to Overweight from Neutral and raised his price target for the shares to $20 from $17. The cybersecurity company closed Friday up 28c to $15.98. A recent round of channel checks showed a "significant improvement" in demand trends for the company, Nowinski tells investors in a research note. The analyst's contacts noted that FireEye's new pricing bundles are having a positive impact on overall demand trends, which he believes is sustainable and will drive positive operating income and free cash flow starting in Q3. Nowinski believes FireEye's current valuation represents an attractive entry point.
ASUR Asure Software
$11.64

0.2 (1.75%)

06/29/18
ADAM
06/29/18
NO CHANGE
Target $21
ADAM
Buy
Asure Software weakness a buying opportunity, says Canaccord
Canaccord analyst David Hynes said the recent weakness in Asure Software is a buying opportunity, citing its potential for M&A, its addition to the Russel 2000 index, and the company's build out of its business to have long-term staying power. Hynes has a Buy rating and $21 price target on Asure Software shares.
08/28/18
DOTC
08/28/18
INITIATION
Target $20
DOTC
Buy
Asure Software coverage assumed with a Buy at Dougherty
Dougherty analyst Jeremy Hamblin assumed coverage on Asure Software with a Buy and $20 price target.
08/21/18
LSCM
08/21/18
NO CHANGE
Target $20
LSCM
Buy
Asure Software an 'underappreciated' turnaround story, says Lake Street
Lake Street analyst Eric Martinuzzi reiterated a Buy rating and $20 price target on Asure Software following the company's "solid" Q2 report and backed FY18 guidance. The analyst says that he does not have any company-specific reasons for recent stock weakness, but part of the pullback may be new investors who bought the June 14 follow-on offering at $17.50 expecting upside to Q2 revenue, but only saw an inline revenue print. Asure is an "underappreciated" turnaround story sustaining double-digit organic growth, the analyst contends.
08/23/18
BRRR
08/23/18
NO CHANGE
Target $25
BRRR
Outperform
Asure recent weakness brings buying opportunity, says Barrington
Barrington analyst Vincent Colicchio views the recent weakness in shares of Asure Software as a buying opportunity. The stock has declined 19% since the company's secondary equity offering on June 18, and 4% since its last earnings call, which provides an "attractive buying opportunity," Colicchio tells investors in a research note. The analyst says Asure's consistent record of generating double-digit organic growth, large cross-selling potential and acquisition strategy make him optimistic about its long-term growth potential. He keeps an Outperform rating on the name with a $25 price target.
ATNI ATN International
$70.81

-1.04 (-1.45%)

07/27/18
RAJA
07/27/18
DOWNGRADE
RAJA
Market Perform
ATN International downgraded to Market Perform from Outperform at Raymond James
07/27/18
07/27/18
DOWNGRADE

Market Perform
ATN International downgraded to Market Perform on valuation at Raymond James
As previously reported, Raymond James downgraded ATN International to Market Perform from Outperform. Analyst Ric Prentiss said shares have "surged" past his prior price target of $63 following the in-line quarter.
04/27/18
BWSF
04/27/18
DOWNGRADE
Target $45
BWSF
Sell
ATN International downgraded to Sell from Hold at BWS Financial
BWS Financial analyst Hamed Khorsand downgraded ATN International to Sell from Hold and lowered his price target on the stock to $45 from $57 following the company's Q1 report. He believes there could be declining earnings ahead given that he thinks the company could see a low rate of return as it rebuilds the network in the Virgin Islands. He also sees signs of wear in other areas of ATN's portfolio that could result in lower free cash flow in subsequent quarters, he tells investors.
01/08/18
SIDC
01/08/18
UPGRADE
Target $70
SIDC
Buy
ATN International upgraded to Buy from Neutral at Sidoti
Sidoti analyst Allen Klee upgraded ATN International to Buy and raised its price target to $70 from $64 to reflect improving operations in the US Virgin Islands and lower US corporate tax rates.
ROG Rogers Corporation
$142.02

0.06 (0.04%)

12/19/17
NEED
12/19/17
NO CHANGE
Target $180
NEED
Buy
Rogers Corporation price target raised to $180 from $165 at Needham
Needham analyst Sean Hannan raised his price target on Rogers Corp to $180 after "positive" investor meetings with the company management. Hannan says the "niche-dominating" company continues to see "good growth" in specialized markets requiring its engineered materials. The analyst says he is especially enthusiastic about favorable trends in Advanced Mobility, Advanced Connectivity and Safety as they benefit from automotive technology improvements.
09/18/18
RILY
09/18/18
NO CHANGE
Target $180
RILY
Buy
Rogers Corporation price target raised to $180 from $150 at B. Riley FBR
B. Riley FBR analyst Craig Ellis raised his price target for Rogers Corporation to $180 and keeps a Buy rating on the shares. Recent company and broader checks on secular technology adoption for key drivers continue to track well, Ellis tells investors in a research note.
CERS Cerus
$7.02

-0.08 (-1.13%)

01/04/18
CANT
01/04/18
INITIATION
Target $5
CANT
Overweight
Cerus assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage of Cerus with an Overweight rating and $5 price target.
07/20/18
CANT
07/20/18
NO CHANGE
Target $9
CANT
Overweight
Cerus price target raised to $9 from $7 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou raised his price target for Cerus to $9 and reiterates an Overweight rating on the shares after hosting investor meetings with management. The analyst is now more confident that the company's recent momentum should continue. He believes Cerus has "various growth drivers for the next several years". The FDA is moving closer to providing final guidance for methods to reduce bacterial contamination in transfused platelets, and Cerus' pathogen-inactivation technology should be included, Bijou tells investors in a research note.
JE Just Energy
$3.26

-0.12 (-3.55%)

02/08/18
02/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wynn Resorts (WYNN) upgraded to Positive from Neutral at Susquehanna with analyst Rachael Rothman saying the resignation of Steve Wynn removes an overhang. 2. Molson Coors (TAP) upgraded to Hold from Sell at Berenberg with analyst Javier Gonzalez Lastra saying he sees limited downside from the current share price and thinks greater cost savings could be a near-term upside catalyst. 3. Humana (HUM) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying after ceding market share for "several years," Humana should return to above market individual Medicare Advantage enrollment growth in 2019 as it benefits from a favorable rate update and tax reform. 4. Anadarko (APC) upgraded to Outperform from Neutral at Macquarie with analyst Paul Grigel saying he sees sustainable upside into 2018 due to continued strong growth in US production, infrastructure and its advantage in the DJ Basin. 5. Just Energy (JE) was upgraded to Outperformer from Neutral at CIBC and to Buy from Hold at Canaccord. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/21/18
NATB
08/21/18
DOWNGRADE
NATB
Sector Perform
Just Energy downgraded to Sector Perform from Outperform at National Bank
08/10/18
CIBC
08/10/18
DOWNGRADE
CIBC
Neutral
Just Energy downgraded to Neutral from Outperformer at CIBC
05/17/18
ADAM
05/17/18
DOWNGRADE
ADAM
Hold
Just Energy downgraded to Hold from Buy at Canaccord
MELI MercadoLibre
$354.24

0.29 (0.08%)

08/22/18
STFL
08/22/18
UPGRADE
Target $380
STFL
Buy
MercadoLibre upgraded to Buy from Hold at Stifel
Stifel analyst Scott Devitt upgraded MercadoLibre to Buy from Hold with a $380 price target. In a research note to investors, the analyst says he believes Q2 was a "transitional" quarter and that management reacted quickly to the Correios price increase by finding the right balance between growth and profitability to position the company well for the long term. Devitt, who says he believes recent stock price weakness represents an opportunity to become more constructive on shares, adds that in a bull case scenario, he believes shares could possibly reach $446 over the next 12 months.
08/21/18
STFL
08/21/18
UPGRADE
STFL
Buy
MercadoLibre upgraded to Buy from Hold at Stifel
08/22/18
08/22/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1.Systemax (SYX) upgraded to Buy from Neutral at Sidoti with analyst Anthony Lebiedzinski saying the recent selloff in shares is overdone. 2. Itron (ITRI) upgraded to Buy from Hold at Argus with analyst John Eade saying while the stock price has trended in a bearish pattern until recently and latest earnings have underperformed, its bookings appear to be in "solid shape." 3. Landstar System (LSTR) upgraded to Outperform from Market Perform at Wells Fargo with analyst Casey Deak saying he has become more positive on the brokerage space moving into 2019. 4. YRC Worldwide (YRCW) upgraded to Buy from Hold at Deutsche Bank with analyst Amit Mehrotra saying he believes continued pricing and yield improvement, renewal of YRC's aging fleet and opportunities to improve labor flexibility and driver productivity will drive better equity value. 5. MercadoLibre (MELI) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he believes Q2 was a "transitional" quarter and that management reacted quickly to the Correios price increase by finding the right balance between growth and profitability to position the company well for the long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/18
BRSE
09/27/18
UPGRADE
BRSE
Outperform
MercadoLibre upgraded to Outperform from Neutral at Bradesco
REX REX American Resources
$78.47

2.59 (3.41%)

KEYS Keysight Technologies
$66.11

0.305 (0.46%)

08/22/18
SBSH
08/22/18
NO CHANGE
Target $73
SBSH
Buy
Keysight Technologies price target raised to $73 on Q3 beat at Citi
Keysight Technologies' Q3 results last night clearly show the positive impact from the multi-year 5G cycle that lays ahead, Citi analyst Jim Suva tells investors in a research note. The analyst believes the multi-year benefit to the company from the 5G deployment "has only started." He raised his price target for Keysight shares to $73 from $71 and keeps a Buy rating on the name.
08/22/18
JEFF
08/22/18
NO CHANGE
Target $74
JEFF
Buy
Keysight Technologies price target raised to $74 from $63 at Jefferies
Jefferies analyst Brandon Couillard raised his price target for Keysight Technologies to $74 citing last night's "big" beat and raise quarter. The results reflect accelerating fundamentals across the board and good momentum moving into Q4, Couillard tells investors in a post-earnings research note. The analyst believes Keysight remains "very well positioned to benefit from multiple big growth areas." He keeps a Buy rating on the shares.
08/22/18
BARD
08/22/18
NO CHANGE
Target $73
BARD
Outperform
Keysight Technologies price target raised to $73 from $61 at Baird
Baird analyst Richard Eastman raised his price target on Keysight Technologies to $73 from $61 following strong Q3 results and raised guidance. The analyst said the earnings beat was high quality and he sees a further runway for growth. Eastman reiterated his Outperform rating on Keysight Technologies shares.
08/22/18
DBAB
08/22/18
NO CHANGE
Target $80
DBAB
Buy
Keysight Technologies price target raised to $80 from $66 at Deutsche Bank
Deutsche Bank analyst Vijay Bhagavath raised his price target for Keysight Technologies to $80 citing last night's "beat and raise" Q3 results. The analyst maintains his fundamental conviction on Keysight as an "early cycle" idea on "major" multiyear growth themes such as 5G broadband and connected cars. He keeps a Buy rating on the shares.
BERY Berry Global
$47.57

-0.72 (-1.49%)

05/04/18
BARD
05/04/18
NO CHANGE
Target $65
BARD
Outperform
Berry Global shares appear oversold, says Baird
Baird analyst Ghansham Panjabi said weak volumes and an unfavorable cost/spread continue to weigh on Berry Global shares, but at this point the shares appear oversold. The analyst believes its free cash flow and volume outlook are move favorable and he sees pricing pressures easing over the next 2-3 quarters. Panjabi reiterated his Outperform rating and lowered his price target to $65 from $70 on Berry Global shares.
05/18/18
JEFF
05/18/18
INITIATION
Target $67
JEFF
Buy
Berry Global initiated with a Buy at Jefferies
Jefferies analyst Daniel Rizzo started Berry Global Group with a Buy rating and $67 price target. The company has one of the highest free cash flow profiles in Packaging, and deleveraging returning cash should drive a multiple expansion, Rizzo tells investors in a research note.
08/07/18
UBSW
08/07/18
DOWNGRADE
Target $54
UBSW
Neutral
Bemis downgraded to Neutral from Buy at UBS
UBS analyst Edlain Rodriguez downgraded Bemis (BMS) to Neutral following Amcor's offer to acquire the company. The analyst raised his price target for the shares to $54 from $52, which reflects a 50/50 blend of his standalone Bemis target of $52 and the implied current deal price of $55. Rodriguez says the closest plastic packaging peers to Bemis are Sealed Air (SEE), Berry Global (BERY) and Sonoco Products (SON).
08/15/18
RBCM
08/15/18
UPGRADE
Target $54
RBCM
Sector Perform
Bemis upgraded to Sector Perform at RBC Capital on expected Amcor deal approval
As reported earlier, RBC Capital analyst Arun Viswanathan upgraded Bemis to Sector Perform from Underperform and raised his price target to $54 from $44, saying that while he is cautious about the company's food packaging business, he expects the previously announced acquisition by Amcor to be approved by all parties with minimal divestitures. The analyst further states that the two companies are highly complementary and the combination should yield about $180M in synergies. Viswanathan also likes Berry Global (BERY) and Graphic Packaging Holding (GPK) based on their attractive valuation.
ITW Illinois Tool Works
$143.70

-1.04 (-0.72%)

07/24/18
WELS
07/24/18
NO CHANGE
Target $160
WELS
Outperform
Illinois Tool Works price target lowered to $160 from $170 at Wells Fargo
Wells Fargo analyst Andrew Casey lowered his price target for Illinois Tool Works to $160 from $170 as its underlying investment case hit another pothole in Q2. In the short-term, the analyst believes the company's operating profit shortfall and decreased earnings guidance likely weighed on the stock. Nonetheless, Casey believes the underlying fundamentals remain solid, and the selloff presents a good entry point. He reiterates an Outperform rating on the shares.
07/24/18
FBCO
07/24/18
NO CHANGE
Target $146
FBCO
Neutral
Illinois Tool Works price target lowered to $146 from $166 at Credit Suisse
Credit Suisse analyst Jamie Cook lowered his price target for Illinois Tool Works to $146 from $166 after the company reported an in-line quarter but lowered full year guidance by 10c largely on FX. The analyst reiterates a Neutral rating on the shares.
07/24/18
SBSH
07/24/18
NO CHANGE
Target $166
SBSH
Buy
Illinois Tool Works selloff yesterday a buying opportunity, says Citi
Citi analyst Andrew Kaplowitz recommends using the selloff yesterday in shares of Illinois Tool Works as a buying opportunity. Despite "disappointing" guidance, the fundamental strengths of Illinois Tool Works' "diversified" portfolio and focused business model is not materially changed, Kaplowitz tells investors in a post-earnings research note. He believes the currency and cost headwinds pressuring the near-term outlook should detract from the company's "durable strengths." Kaplowitz lowered his price target for Illinois Tool Works to $166 from $187 and keeps a Buy rating on the name.
08/20/18
MSCO
08/20/18
INITIATION
Target $146
MSCO
Equal Weight
Illinois Tool Works initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Joshua Pokrzywinski initiated Illinois Tool Works with an Equal Weight rating and a price target of $146. The analyst notes that while the company is "positioned as a defensive industrial" based on the high quality nature of its portfolio, its markets are cyclical, with less room for margin expansion to come in the next 12 months. While he does not believe that Illinois Tool Works cut operating costs "too deep to grow", he notes that "there has been both organic and M&A opportunity cost" in its capital decision.
OPHT Ophthotech
$2.53

0.08 (3.27%)

03/19/18
JPMS
03/19/18
DOWNGRADE
JPMS
Underweight
Ophthotech downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama downgraded Ophthotech to Underweight without a price target. The analyst believes it will take "definitive proof-of-concept data to ascribe credit to the Zimura franchise overall." With clinical data not expected until the end of 2018, Rama expects shares of Ophthotech to underperform.
COT Cott Corp.
$15.10

-0.345 (-2.23%)

09/28/18
JPMS
09/28/18
NO CHANGE
Target $21
JPMS
Overweight
Cott Corp. added to Analyst Focus List at JPMorgan
JPMorgan analyst Peter Grom added Cott Corp. to his firm's Analyst Focus List saying he sees "plenty of room" for shares to outperform through the balance of 2018 and into 2019. The analyst sees improved visibility for both 2018 and 2019 EBITDA after Cott issued a presentation that discussed the company's broader strategy and underlying trends. Further, the shares are still trading at a 19% discount to route-based peers, Grom tells investors in a research note. He keeps an Overweight rating on the stock with a $21 price target.
08/17/18
08/17/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dare Bioscience (DARE) initiated with a Buy at Maxim. 2. WillScot (WSC) initiated with an Outperform at Credit Suisse. 3. Ligand (LGND) initiated with a Neutral at Goldman Sachs. 4. Cott Corp. (COT) initiated with an Action List Buy at TD Securities. 5. Azure Power (AZRE) initiated with a Buy at Janney Montgomery Scott. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/01/18
JPMS
06/01/18
UPGRADE
JPMS
Overweight
Cott reinstated with an Overweight from Neutral at JPMorgan
JPMorgan analyst Peter Grom reinstated coverage of Cott Corp. and upgraded the shares to Overweight from Neutral with a $19 price target. The current 21% discount to peers provides a compelling entry point, Grom tells investors in a research note. He believes the company's new business model improves visibility and limits volatility.
08/17/18
TDSI
08/17/18
INITIATION
TDSI
Action List Buy
Cott Corp. initiated with an Action List Buy at TD Securities
PMTS CPI Card Group
$3.00

(0.00%)

10/10/17
CHLM
10/10/17
NO CHANGE
CHLM
Green Dot, CPI Card added to Favorite Near-Term Risk/Reward List at Craig-Hallum
Craig-Hallum analyst Brad Berning added Green Dot (GDOT) and CPI Card Group (PMTS) to his Favorite Near-Term Risk/Reward List, saying he expects the former's positive momentum and estimate revisions to continue while believing the current quarter and 4Q outlook can be a positive catalyst for the latter. The analyst also sees positive near-term catalysts for Blackhawk (HAWK), LendingClub (LC), Verifone (PAY) and BofI Holding (BOFI).
LMNX Luminex
$28.72

-0.17 (-0.59%)

05/07/18
DBAB
05/07/18
UPGRADE
Target $22
DBAB
Hold
Luminex upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Dan Leonard upgraded Luminex to Hold and raised his price target for the shares to $22 from $19. The analyst views the risk/reward as balanced at current share levels.
09/27/18
PIPR
09/27/18
NO CHANGE
PIPR
Neutral
Piper says about $3.5M of Luminex revenue at risk from Medicare determination
After Palmetto's MolDx released a final local coverage determination that panels of 3-5 pathogens will be covered, but larger panels will not be, Piper Jaffray analyst William Quirk said he believes 51% of the population is covered by MACs that follow MolDX. In terms of the decision's implications for Luminex, Quirk said he sees $3M-$4M in exposure to MolDx Medicare for Luminex's xTAG and Nanosphere tests. He also noted that Luminex management has talked about unbundling to make their panels smaller, which he believes will be the likely outcome. Quirk has a Neutral rating on Luminex shares.
YGYI Youngevity
$6.78

-0.6 (-8.13%)

08/10/18
BNCH
08/10/18
INITIATION
Target $7
BNCH
Buy
Youngevity initiated with a Buy at Benchmark
Benchmark started Youngevity with a Buy rating and $7 price target.
08/10/18
08/10/18
INITIATION
Target $7

Buy
Benchmark starts Youngevity with Buy rating, $7 price target
As previously reported, Benchmark analyst Bill Sutherland started Youngevity with a Buy rating and $7 price target, stating that he believes the stock has yet to reflect a return to organic revenue growth and rising margins for the Direct Selling segment as well as a just-announced, 5-year green coffee bean supply contract that he believes should push the Coffee segment to "meaningful profitability" in 2019.
OTCM OTC Markets
$0.00

(0.00%)

TODAY'S FREE FLY STORIES

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

, INCY

Incyte

$66.09

1.66 (2.58%)

18:44
10/21/18
10/21
18:44
10/21/18
18:44
Hot Stocks
Eli Lilly, Incyte shares updated safety analysis of Olumiant in active RA »

Eli Lilly (LLY) and…

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

INCY

Incyte

$66.09

1.66 (2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

WAL

Western Alliance

$49.42

-4.11 (-7.68%)

18:36
10/21/18
10/21
18:36
10/21/18
18:36
Recommendations
Western Alliance analyst commentary  »

Western Alliance should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

FFBC

First Financial Bancorp

$24.91

-2.51 (-9.15%)

18:32
10/21/18
10/21
18:32
10/21/18
18:32
Upgrade
First Financial Bancorp rating change  »

First Financial upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

HRZN

Horizon Technology

$11.45

0.06 (0.53%)

18:29
10/21/18
10/21
18:29
10/21/18
18:29
Downgrade
Horizon Technology rating change  »

Horizon Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

NCNA

NuCana

$18.90

1.9 (11.18%)

18:25
10/21/18
10/21
18:25
10/21/18
18:25
Recommendations
NuCana analyst commentary  »

NuCana updated Phase Ib…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

CBNK

Capital Bancorp

$12.75

(0.00%)

18:25
10/21/18
10/21
18:25
10/21/18
18:25
Initiation
Capital Bancorp initiated  »

Capital Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.19

0.005 (0.04%)

, GOLD

Randgold

$81.91

0.23 (0.28%)

18:03
10/21/18
10/21
18:03
10/21/18
18:03
Hot Stocks
ISS recommends Barrick, Randgold shareholders vote in favor of merger »

Barrick Gold (ABX)…

ABX

Barrick Gold

$13.19

0.005 (0.04%)

GOLD

Randgold

$81.91

0.23 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$140.06

0.74 (0.53%)

, IBM

IBM

$129.16

-1.36 (-1.04%)

17:45
10/21/18
10/21
17:45
10/21/18
17:45
Hot Stocks
Visa readies B2B Connect for market »

Visa (V) announced new…

V

Visa

$140.06

0.74 (0.53%)

IBM

IBM

$129.16

-1.36 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 28

    Oct

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

  • 29

    Jan

  • 03

    Mar

T

AT&T

$32.86

0.36 (1.11%)

, CMCSA

Comcast

$35.97

0.02 (0.06%)

17:42
10/21/18
10/21
17:42
10/21/18
17:42
Hot Stocks
Box Office Battle: 'Halloween' breaks records with scary $77.5M »

Comcast (CMCSA)…

T

AT&T

$32.86

0.36 (1.11%)

CMCSA

Comcast

$35.97

0.02 (0.06%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.66

-0.38 (-0.68%)

FOX

21st Century Fox

$45.51

0.05 (0.11%)

FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

LGF.A

Lionsgate

$22.20

(0.00%)

DIS

Disney

$118.81

2.55 (2.19%)

VIAB

Viacom

$33.24

-0.49 (-1.45%)

VIA

Viacom

$36.75

-0.48 (-1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 14

    Nov

  • 14

    Nov

FOX

21st Century Fox

$45.51

0.05 (0.11%)

, FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

17:24
10/21/18
10/21
17:24
10/21/18
17:24
Periodicals
AMC's Collier named next leader of Fox Network, NY Times reports »

Fox (FOXA) will turn to…

FOX

21st Century Fox

$45.51

0.05 (0.11%)

FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

AMC

AMC Entertainment

$19.81

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

VLKAY

Volkswagen

$0.00

(0.00%)

17:04
10/21/18
10/21
17:04
10/21/18
17:04
Periodicals
Audi electric SUV facing delay due to software bug, Reuters reports »

Audi's first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$34.66

-0.61 (-1.73%)

17:00
10/21/18
10/21
17:00
10/21/18
17:00
Periodicals
Blackstone to acquire Ulterra for $700M, Reuters reports »

Blackstone has agreed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

, KKR

KKR

$24.22

-0.45 (-1.82%)

16:56
10/21/18
10/21
16:56
10/21/18
16:56
Periodicals
Fiat agrees to sell Magneti Marelli to KKR's Calsonic, Bloomberg says »

Fiat Chrysler (FCAU) has…

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

KKR

KKR

$24.22

-0.45 (-1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 30

    Oct

MRK

Merck

$72.34

0.12 (0.17%)

, AZN

AstraZeneca

$39.21

0.25 (0.64%)

16:40
10/21/18
10/21
16:40
10/21/18
16:40
Hot Stocks
Merck, AstraZeneca announce detailed results from Phase 3 SOLO-1 trial »

AstraZeneca (AZN) and…

MRK

Merck

$72.34

0.12 (0.17%)

AZN

AstraZeneca

$39.21

0.25 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 11

    Jan

  • 16

    Feb

VAR

Varian Medical

$104.25

-1.575 (-1.49%)

16:31
10/21/18
10/21
16:31
10/21/18
16:31
Hot Stocks
Varian unveils new Bravos afterloader system for brachytherapy treatments »

Varian announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

14:30
10/21/18
10/21
14:30
10/21/18
14:30
Conference/Events
Neon Therapeutics management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 07

    Nov

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13
Hot Stocks
G1 presents additional data from randomized Phase 2 trial in first-line SCLC »

G1 Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NCNA

NuCana

$18.90

1.9 (11.18%)

14:09
10/21/18
10/21
14:09
10/21/18
14:09
Hot Stocks
NuCana reports additional data on NUC-1031 in advanced biliary tract cancer »

NuCana announced combined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

, MRK

Merck

$72.34

0.12 (0.17%)

14:05
10/21/18
10/21
14:05
10/21/18
14:05
Hot Stocks
Leap Therapeutics presents esophagogastric cancer data »

Leap Therapeutics (LPTX)…

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

INCY

Incyte

$66.09

1.66 (2.58%)

14:02
10/21/18
10/21
14:02
10/21/18
14:02
Hot Stocks
Incyte announces positive interim data from Phase 2 trial of Pemigatinib »

Incyte announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58
Hot Stocks
Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer »

Bayer (BAYRY) and Loxo…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53
Hot Stocks
Loxo announces larotrectinib clinical update in patients with TRK fusion cancers »

Loxo Oncology (LOXO)…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

13:45
10/21/18
10/21
13:45
10/21/18
13:45
Hot Stocks
Mirati announces updated data from ongoing trial of single agent sitravatinib »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39
Hot Stocks
Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34
Hot Stocks
Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib »

Gilead Sciences (GILD)…

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.